Amylyx Pharmaceuticals Inc (AMLX)

Amylyx Pharmaceuticals Inc (AMLX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $3.6B; returns 1 day -4.8%, 1 week +3.3%, 1 year +90.1%.

Amylyx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and endocrine diseases. The company's business model transitioned significantly in April 2024 following the voluntary withdrawal of its primary commercial product, AMX0035 (marketed as RELYVRIO in the U.S.

Groups AMLX belongs to

• Biotechnology
• Biopharmaceutical
• Healthcare
• Clinical Stage
• Clinical Stage Biotech
• Neuroscience
• Endocrinology
• Rare Diseases
• Drug Discovery
• Neurological Disorders
• R&D

AMLX financial model: income statement, cash flow and balance sheet